What is Lantus CARTRIDGE?
Lantus CARTRIDGE (Lantus CARTRIDGE) is a man-made form of a hormone that is produced in the body. Lantus CARTRIDGE is a hormone that works by lowering levels of glucose (sugar) in the blood. Lantus CARTRIDGE is a long-acting Lantus CARTRIDGE that starts to work several hours after injection and keeps working evenly for 24 hours.
The Lantus CARTRIDGE SoloStar injection pen is used to improve blood sugar control in adults with diabetes mellitus.
Lantus CARTRIDGE is used to treat type 1 diabetes or type 2 diabetes in adults.
It is not known if Lantus CARTRIDGE is safe and effective in children.
Lantus CARTRIDGE indications
Lantus CARTRIDGE injection is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Limitations of Use
Lantus CARTRIDGE injection is not recommended for the treatment of diabetic ketoacidosis.
How should I use Lantus CARTRIDGE?
Use Lantus CARTRIDGE cartridge systems as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Extra patient leaflets are available with Lantus CARTRIDGE cartridge systems. Talk to your pharmacist if you have questions about this information.
- Use Lantus CARTRIDGE cartridge systems at the same time each day, as directed by your doctor.
- A health care provider will teach you how to use Lantus CARTRIDGE cartridge systems. Be sure you understand how to use it. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Wash your hands before you use Lantus CARTRIDGE cartridge systems.
- Always check before each use to be sure you are injecting the correct dose of Lantus CARTRIDGE. Using too much or too little Lantus CARTRIDGE may result in serious side effects.
- Lantus CARTRIDGE cartridge systems should be clear and colorless. Do not use Lantus CARTRIDGE cartridge systems if it contains particles or is discolored, or if the container is cracked or damaged.
- Do NOT dilute Lantus CARTRIDGE cartridge systems or mix it with other Lantus CARTRIDGE. Do NOT use it in an Lantus CARTRIDGE pump.
- Use the proper technique taught to you by your doctor. Inject deep under the skin, NOT into a vein or muscle.
- Injection sites within an injection area (abdomen, thigh, or upper arm) must be rotated from one injection to the next.
- Be sure you have purchased the correct Lantus CARTRIDGE. Lantus CARTRIDGE comes in a variety of containers, including vials, cartridges, and pens. Make sure that you understand how to properly measure and prepare your dose. If you have any questions about measuring and preparing your dose, contact your doctor or pharmacist for information.
- The effect of Lantus CARTRIDGE cartridge systems lasts for up to 24 hours.
- Lantus CARTRIDGE cartridge systems begins lowering blood sugar about 1 to 2 hours after an injection. There is no peak effect. The effect lasts for up to 24 hours.
- Do not mix this Lantus CARTRIDGE together with any other type of Lantus CARTRIDGE or any other medicine in the same syringe.
- Do not share pen or cartridge devices with another person. Sharing these devices may pass infections from one person to another. This includes infections you may not know you have.
- Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- It is very important to follow your Lantus CARTRIDGE regimen exactly. Do NOT miss any doses. Ask your doctor for specific instructions to follow in case you ever miss a dose of Lantus CARTRIDGE.
Ask your health care provider any questions you may have about how to use Lantus CARTRIDGE cartridge systems.
Uses of Lantus CARTRIDGE in details
Lantus CARTRIDGE is used to reduce high blood sugar (glucose) levels in people with diabetes mellitus.
Lantus CARTRIDGE description
Each mL contains 100 IU Lantus CARTRIDGE, 0.27% w/v m-cresol as preservative and water for injection.
Lantus CARTRIDGE injection [ribosomal deoxyribonucleic acid (rDNA)] is a recombinant human Lantus CARTRIDGE analogue produced by recombinant DNA technology. Lantus CARTRIDGE differs from human Lantus CARTRIDGE in that the amino acid asparagine at position A21 is replaced by glycine and 2 arginines are added to the C-terminus of B-chain.
Chemically, it is 21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human Lantus CARTRIDGE and has the empirical formula C267H404N72O78S6 and a molecular weight of 6,063.
Lantus CARTRIDGE is an Lantus CARTRIDGE analogue, equipotent to human Lantus CARTRIDGE, with a peakless glucose lowering profile and a prolonged duration of action that permits once daily dosing.
Lantus CARTRIDGE dosage
Lantus CARTRIDGE Dosage
Generic name: Lantus CARTRIDGE 100[iU] in 1mL
Dosage form: injection, solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Important Administration Instructions
- Always check Lantus CARTRIDGE labels before administration.
- Train patients on proper use and injection technique before initiating Lantus CARTRIDGE.
- Visually inspect Lantus CARTRIDGE KwikPen for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles.
- Inject between 1 and 80 units per injection.
- Administer Lantus CARTRIDGE subcutaneously into the abdominal area, thigh, or deltoid, and rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy.
- Do not dilute or mix Lantus CARTRIDGE with any other Lantus CARTRIDGE or solution as the onset of action or time to peak effect of Lantus CARTRIDGE and the mixed Lantus CARTRIDGE may be altered in an unpredictable manner.
- Do not administer intravenously or via an Lantus CARTRIDGE pump because this could result in severe hypoglycemia.
General Dosing Instructions
- In patients with type 1 diabetes, Lantus CARTRIDGE must be used concomitantly with short-acting Lantus CARTRIDGE.
- Inject Lantus CARTRIDGE subcutaneously once daily at any time of day but at the same time every day.
- Individualize and titrate the dosage of Lantus CARTRIDGE based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function and should be made under medical supervision with appropriate glucose monitoring.
Initiation of Lantus CARTRIDGE Therapy
- The recommended starting dose of Lantus CARTRIDGE in patients with type 1 diabetes should be approximately one-third of the total daily Lantus CARTRIDGE requirements. Short- or rapid-acting, pre-meal Lantus CARTRIDGE should be used to satisfy the remainder of the daily Lantus CARTRIDGE requirements.
- The recommended starting dose of Lantus CARTRIDGE in patients with type 2 diabetes is 0.2 units/kg or up to 10 units once daily. One may need to adjust the amount and timing of short- or rapid-acting insulins and dosages of any anti-diabetic drugs.
Changing to Lantus CARTRIDGE from Other Lantus CARTRIDGE Therapies
- If changing patients from another Lantus CARTRIDGE product, 100 units/mL, to Lantus CARTRIDGE, the dose of Lantus CARTRIDGE should be the same as the other Lantus CARTRIDGE product, 100 units/mL, and the time of day for administration should be determined by the physician.
- If changing patients from a once-daily Lantus CARTRIDGE product, 300 units/mL, to once-daily Lantus CARTRIDGE, the recommended initial Lantus CARTRIDGE dosage is 80% of the Lantus CARTRIDGE product, 300 units/mL, dose that is being discontinued. This dosage reduction will lower the likelihood of hypoglycemia.
- If changing from a treatment regimen with an intermediate- or long-acting Lantus CARTRIDGE (other than an Lantus CARTRIDGE product, 100 units/mL) to a regimen with Lantus CARTRIDGE, a change in the dose of the basal Lantus CARTRIDGE may be required and the amount and timing of shorter-acting insulins and doses of any anti-diabetic drugs may need to be adjusted.
- If changing patients from twice-daily NPH Lantus CARTRIDGE to once-daily Lantus CARTRIDGE, the recommended initial Lantus CARTRIDGE dosage is 80% of the total NPH dosage that is being discontinued. This dosage reduction will lower the likelihood of hypoglycemia.
More about Lantus CARTRIDGE (Lantus CARTRIDGE)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Espanol
- 0 Reviews - Add your own review/rating
Consumer resources
- Lantus CARTRIDGE
- Lantus CARTRIDGE KwikPen
- Lantus CARTRIDGE (Advanced Reading)
- Other brands: Lantus, Lantus CARTRIDGE, Lantus CARTRIDGE Solostar, Lantus Solostar
Professional resources
- Lantus CARTRIDGE (FDA)
- Lantus CARTRIDGE (AHFS Monograph)
Related treatment guides
- Diabetes, Type 1
- Diabetes, Type 2
Lantus CARTRIDGE interactions
See also:
What other drugs will affect Lantus CARTRIDGE?
Drugs That May Increase The Risk Of Hypoglycemia
The risk of hypoglycemia associated with Lantus CARTRIDGE use may be increased with antidiabetic agents, (ACE) inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Dose adjustment and increased frequency of glucose monitoring may be required when Lantus CARTRIDGE is co-administered with these drugs.
Drugs That May Decrease The Blood Glucose Lowering Effect Of Lantus CARTRIDGE
The glucose lowering effect of Lantus CARTRIDGE may be decreased when co-administered with atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isonazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline) and thyroid hormones. Dose adjustment and increased frequency of glucose monitoring may be required when Lantus CARTRIDGE is co-administered with these drugs.
Drugs That May Increase Or Decrease The Blood Glucose Lowering Effect Of Lantus CARTRIDGE
The glucose lowering effect of Lantus CARTRIDGE may be increased or decreased when co-administered with alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Dose adjustment and increased frequency of glucose monitoring may be required when Lantus CARTRIDGE is co-administered with these drugs.
Drugs That May Affect Signs And Symptoms Of Hypoglycemia
The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with Lantus CARTRIDGE.
Lantus CARTRIDGE side effects
See also:
What are the possible side effects of Lantus CARTRIDGE?
The following adverse reactions are discussed elsewhere:
- Hypoglycemia.
- Hypersensitivity and allergic reactions.
- Hypokalemia.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Two clinical trials with Lantus CARTRIDGE were conducted: one in type 1 diabetes and one in type 2 diabetes.
The type 1 diabetes population had the following characteristics: Mean age was 41 years and mean duration of diabetes was 16 years. 58% were male. 75% were Caucasian, 2% Black or African American and 4% American Indian or Alaskan native. 4% were Hispanic. At baseline, mean eGFR was 109 mL/min/1.73m². 73.5 percent of patients had eGFR > 90 mL/min/1.73m². The mean BMI was approximately 26 kg/m². HbA1c at baseline was 7.8%. The data in Table 1 reflect exposure of 268 patients to Lantus CARTRIDGE with a mean exposure duration of 49 weeks.
The type 2 diabetes population had the following characteristics: Mean age was 59 years and mean duration of diabetes was 11 years. 50% were male. 78% were Caucasian, 8% Black or African American and 5% American Indian or Alaskan native. 28% were Hispanic. At baseline, mean eGFR was 109 mL/min/1.73m². 67.5 percent of patients had eGFR > 90 mL/min/1.73m². The mean BMI was approximately 32 kg/m². HbA1c at baseline was 8.3%. The data in Table 2 reflect exposure of 376 patients to Lantus CARTRIDGE with a mean exposure duration of 22 weeks.
Common adverse reactions were defined as reactions occurring in ≥ 5% of the population studied. Common adverse reactions during clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus (other than hypoglycemia) are listed in Table 1 and Table 2, respectively.
Table 1: Adverse reactions occurring in ≥ 5% of adult patients with type 1 diabetes treated with Lantus CARTRIDGE in a 52-week trial
Lantus CARTRIDGE + Lantus CARTRIDGE Lispro, % (n=268) | |
Infection Infections other than nasopharyngitis or upper respiratory tract infection. |
The frequencies of adverse reactions during a clinical trial of 5 years duration with another Lantus CARTRIDGE product, 100 units/mL, in patients with type 2 diabetes mellitus are listed in Table 3.
Table 3: Common adverse reactions in 5-year trial of adult patients with type 2 diabetes (adverse reactions with incidence ≥ 10% and higher with another Lantus CARTRIDGE product, 100 units/mL, than comparator)
Another Lantus CARTRIDGE Product, % (n=514) | NPH, % (n=503) | |
Hypertension | 20 | 19 |
Sinusitis | 19 | 18 |
Cataract | 18 | 16 |
Bronchitis | 15 | 14 |
Back pain | 13 | 12 |
Cough | 12 | 7 |
Urinary tract infection | 11 | 10 |
Diarrhea | 11 | 10 |
Depression | 11 | 10 |
Headache | 10 | 9 |
The frequencies of adverse reactions during clinical trials with another Lantus CARTRIDGE product, 100 units/mL, in children and adolescents with type 1 diabetes mellitus are listed in Table 4.
Table 4: Adverse reactions in a 28-week clinical trial of children and adolescents with type 1 diabetes (adverse reactions with frequency ≥ 5% and the same or higher with another Lantus CARTRIDGE product, 100 units/mL, than comparator)
Another Lantus CARTRIDGE Product, % (n=174) | NPH, % (n=175) | |
Rhinitis | 5 | 5 |
Severe Hypoglycemia
Hypoglycemia is the most commonly observed adverse reaction in patients using Lantus CARTRIDGE, including Lantus CARTRIDGE. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, Lantus CARTRIDGE dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for Lantus CARTRIDGE with the incidence of hypoglycemia for other products may be misleading and also, may not be representative of hypoglycemia rates that will occur in clinical practice.
Severe symptomatic hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a blood glucose below 50 mg/dL ( ≤ 56 mg/dL in the 5-year trial and ≤ 36 mg/dL in the ORIGIN trial) or prompt recovery after oral carbohydrate, intravenous glucose or glucagon administration.
The incidence of severe symptomatic hypoglycemia in patients receiving Lantus CARTRIDGE with type 1 diabetes mellitus and type 2 diabetes mellitus was 4% at 52 weeks and 1% at 24 weeks, respectively.
The incidence of severe symptomatic hypoglycemia in a clinical trial with another Lantus CARTRIDGE product, 100 units/mL, in children and adolescents age 6 to 15 years with type 1 diabetes was 23% at 26 weeks.
Table 5 displays the proportion of patients experiencing severe symptomatic hypoglycemia in another Lantus CARTRIDGE product, 100 units/mL, and Standard Care groups in the ORIGIN Trial.
Table 5: Severe Symptomatic Hypoglycemia in the ORIGIN Trial
ORIGIN Trial Median duration of follow-up: 6.2 years | ||
Another Lantus CARTRIDGE Product, 100 units/mL (N=6231) | Standard Care (N=6273) | |
Percent of patients | 6 | 2 |
Allergic Reactions
Some patients taking Lantus CARTRIDGE therapy, including Lantus CARTRIDGE have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported.
Peripheral Edema
Some patients taking Lantus CARTRIDGE have experienced sodium retention and edema, particularly if previously poor metabolic control is improved by intensified Lantus CARTRIDGE therapy.
Lipodystrophy
Administration of Lantus CARTRIDGE subcutaneously, including Lantus CARTRIDGE, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) in some patients.
Weight Gain
Weight gain has occurred with some Lantus CARTRIDGE therapies including Lantus CARTRIDGE and has been attributed to the anabolic effects of Lantus CARTRIDGE and the decrease in glycosuria.
Immunogenicity
As with all therapeutic proteins, there is potential for immunogenicity.
In a 52-week study of type 1 diabetes patients, 42% of patients who received Lantus CARTRIDGE once daily were positive for anti-drug antibodies (ADA) at least once during the study, including 17% that were positive at baseline and 25% of patients who developed ADA during the study. Sixty-five percent of the ADA positive patients on Lantus CARTRIDGE with antibody testing at week 52 remained ADA positive at week 52.
In a 24-week study of type 2 diabetes patients, 17% of patients who received Lantus CARTRIDGE once daily were positive for ADA at least once during the study. Among the subjects who were positive, 5% had ADA at baseline and 12% developed antibodies during the study. The percent binding of patients positive at baseline on Lantus CARTRIDGE did not increase significantly during the study. Fifty-one percent of the ADA positive patients on Lantus CARTRIDGE with antibody testing at week 24 remained ADA positive at week 24. There was no evidence that these antibodies had an impact on efficacy and safety outcomes.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to Lantus CARTRIDGE with the incidence of antibodies in other studies or to other products may be misleading.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of another Lantus CARTRIDGE product, 100 units/mL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.
Medication errors have been reported in which other Lantus CARTRIDGE products, particularly rapid-acting insulins, have been accidentally administered instead of an Lantus CARTRIDGE product. To avoid medication errors between Lantus CARTRIDGE products and other Lantus CARTRIDGE products, patients should be instructed to always verify the Lantus CARTRIDGE label before each injection.
Lantus CARTRIDGE contraindications
See also:
What is the most important information I should know about Lantus CARTRIDGE?
Lantus CARTRIDGE injection is contraindicated:
- •
- during episodes of hypoglycemia.
- •
- in patients with hypersensitivity to Lantus CARTRIDGE products or any of the excipients in Lantus CARTRIDGE injection.
Active ingredient matches for Lantus CARTRIDGE:
Insulin glargine in India.
Unit description / dosage (Manufacturer) | Price, USD |
100 IU x 1 mL x 3ml | $ 5.82 |
Lantus Cartridge 100 IU x 1mL INJ / 3ml | $ 5.82 |
LANTUS CARTRIDGE inj 100 IU x 1 mL x 3ml (Aventis Pasteur) | $ 5.82 |
Lantus Cartridge 100 IU x 1mL INJ / 3ml | $ 5.82 |
List of Lantus CARTRIDGE substitutes (brand and generic names): | |
Lantus XR (Japan) | |
Lantus® | |
LantusВ® | |
Lentard 40 | |
Lentard 40 40iu/ml VIAL / 10ml | $ 1.56 |
Lente Purified Pork Insulin | |
Injectable; Injection; Insulin 100 units / ml | |
Lentisulin CPI | |
Lentisulin CPI Porcine Insulin Zn suspension400iu INJ / 10ml | $ 0.95 |
Lentisulin HPI | |
Lentisulin HPI Insulin Zn suspension 40iu, Zn 0.096mg, Methylparaben1mg/1ml INJ / 10ml | $ 1.14 |
Lentisulin HPI Insulin Zn suspension 40iu, Zn 0.096mg, Methylparaben1mg/1ml INJ / 10ml | $ 1.14 |
Lentisulin HPI 400 | |
Lentisulin HPI 400 400IU VIAL / 10ml | $ 1.33 |
Lupisulin-M 30 (India) | |
Lupisulin-M 30 40 IU VIAL / 10ml (Lupin) | $ 1.71 |
Lupisulin-M 30 100 IU CATRIDGE / 3ml (Lupin) | $ 1.83 |
Lupisulin-M 50 | |
Lupisulin-M 50 40 IU VIAL / 10ml | |
Lusduna (Estonia, Lithuania, Netherlands, Sweden) | |
Mixtard HM Penfill | |
Mixtard HM Penfill 40iu/10ml INJ / 5x3ml | $ 12.59 |
Mixtard-30 (India) | |
Mixtard-30 30% insulin , 70% insulin, isophane100IU x 1mL PENFILL / 3.5mlx5 (Novo Nordisk) | $ 12.52 |
Mixtard-30 30% insulin , 70% insulin, isophane 100IU x 1mL PENFILL / 3.5mlx5 (Novo Nordisk) | $ 12.52 |
MIXTARD-30 FlexPen 100 IU x 1 mL x 3ml (Novo Nordisk) | $ 3.95 |
Mixtard-30 Novolet (India) | |
Mixtard-30 Novolet 30% Soluble insulin , 70%Insulin, Isophane100IU x 1mL INJ / 3ml (Novo Nordisk) | $ 3.43 |
100 IU x 1 mL x 3ml (Novo Nordisk) | $ 3.43 |
Mixtard-30 Novolet 30% Soluble insulin , 70%Insulin, Isophane 100IU x 1mL INJ / 3ml (Novo Nordisk) | $ 3.43 |
MIXTARD-30 NOVOLET Novolet 100 IU x 1 mL x 3ml (Novo Nordisk) | $ 3.43 |
Mixulin HPI | |
Mixulin HPI Porcine Insulin premix 100iu INJ / 10ml | $ 3.43 |
MIXULIN HPI 40IU INJECTION 1 vial / 10 ML injection each (Cadila Pharmaceuticals Ltd) | $ 1.14 |
Mixulin Hpi 40IU Injection (Cadila Pharmaceuticals Ltd) | $ 0.11 |
Mixulin HPI 30/70 | |
Mixulin HPI 30/70 Porcine Insulin 30%, IsophaneInsulin 70%, 40iu INJ / 10ml | $ 1.14 |
Musulin | |
Novofine | |
NovoFine insulin needles 1's (Novo Nordisk) | |
Novomix-30 (India) | |
Novomix-30 300iu FLEXPEN / 1 (Novo Nordisk) | $ 6.33 |
Novomix-30 Insulin Aspart 300iu PENFILL / 5x3ml (Novo Nordisk) | $ 23.67 |
100 IU x 1 mL x 3ml (Novo Nordisk) | $ 2.50 |
Novomix-30 Soluble insulin aspart 30 %, insulin aspart protamine 70 %.100 IU x 1mL FLEXPEN / 3ml (Novo Nordisk) | $ 6.83 |
Novomix-30 Soluble insulin aspart 30 %, insulin aspart protamine 70 %.100 IU x 1mL PENFILL / 3ml (Novo Nordisk) | $ 2.50 |
NOVOMIX-30 FlexPen 100 IU x 1 mL x 3ml (Novo Nordisk) | $ 6.70 |
NOVOMIX-30 penfill 100 IU x 1 mL x 3mlx5 (Novo Nordisk) | $ 26.65 |
Optisulin (Latvia, Lithuania, Slovakia) | |
Injectable; Injection; Insulin Glargine 100 IU / ml (Dr. Reddy's) | |
OPTISULIN Capsule/ Tablet / / 15 units (Dr. Reddy's) | $ 0.31 |
OPTISULIN Capsule/ Tablet / / 30 units (Dr. Reddy's) | $ 0.51 |
15's (Dr. Reddy's) | $ 0.11 |
OPTISULIN cap 15's (Dr. Reddy's) | $ 0.31 |
Rapisulin HPI (India) | |
Rapisulin HPI neutral insulin soluble 40iu INJ / 10ml (Cadila) | $ 1.14 |
40 IU x 10ml (Cadila) | $ 1.14 |
RAPISULIN HPI 400IU INJECTION 1 vial / 10 ML injection each (Cadila) | $ 1.33 |
See 229 substitutes for Lantus CARTRIDGE |
References
- PubChem. "Insulin glargine". https://pubchem.ncbi.nlm.nih.gov/sub... (accessed September 17, 2018).
- DrugBank. "Insulin Glargine - DrugBank". http://www.drugbank.ca/drugs/DB00047 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lantus CARTRIDGE are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lantus CARTRIDGE. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Lantus CARTRIDGE drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users | % | ||
---|---|---|---|
Useful | 1 | 100.0% |
Consumer reported price estimates
No survey data has been collected yet1 consumer reported time for results
To what extent do I have to use Lantus CARTRIDGE before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Lantus CARTRIDGE. To get the time effectiveness of using Lantus CARTRIDGE drug by other patients, please click here.
Users | % | ||
---|---|---|---|
1 day | 1 | 100.0% |
Consumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology